A landmark clinical trial has established that ropeginterferon alfa-2b-njft, a long-acting interferon treatment, delivers substantial therapeutic benefits for essential thrombocythemia patients regardless of their underlying genetic mutations. The EXCEED-ET trial, published in The Lancet Regional Health – Americas, enrolled 52 patients across multiple centers in the United States and Canada, achieving a 61% complete hematological response rate by month 12.
This North American study confirms and expands upon earlier European findings, demonstrating that the treatment’s effectiveness remains consistent across JAK2, CALR, and MPL driver mutations. Dr. Ruben Mesa, lead investigator at UT Health San Antonio, emphasized the clinical significance of achieving uniform outcomes across genetically distinct patient populations. The treatment profile was marked by manageable side effects with low discontinuation rates, supporting its potential as a viable therapeutic option for this rare blood malignancy affecting approximately 1-2 per 100,000 individuals annually.
Read the full article on GMJ Newsroom.
Was this article helpful?
